{"id":71906,"date":"2017-05-07T10:43:29","date_gmt":"2017-05-07T14:43:29","guid":{"rendered":"http:\/\/valorguardians.com\/blog\/?p=71906"},"modified":"2017-05-07T12:21:12","modified_gmt":"2017-05-07T16:21:12","slug":"fda-approves-new-als-drug","status":"publish","type":"post","link":"https:\/\/www.azuse.cloud\/?p=71906","title":{"rendered":"FDA approves new ALS drug"},"content":{"rendered":"

CNN<\/a> reports that the Federal Drug Administration has approved a new drug to treat amyotrophic lateral sclerosis, or ALS, also known as Lou Gehrig’s disease. The drug, Radicava, also known as edaravone, is the first to be approved since riluzole, which was approved for use in the United States in 1995. <\/p>\n

Tests conducted in Japan found that ALS sufferers who received edaravone experienced a smaller decline in their level of daily functioning compared to those who received a placebo. MT Pharma, the maker of edaravone, said the drug slowed the decline of physical function by 33%.<\/p>\n

“After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States,” Eric Bastings, the deputy director of the FDA’s neurology products division, said in a statement. “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”<\/p><\/blockquote>\n

From Fox6<\/a>;<\/p>\n

The CDC estimates that 12,000 to 15,000 people have ALS in the United States. People usually find out they have it between 55 and 75 years of age. On average, sufferers live two to five years after symptoms develop.<\/p>\n

ALS is slightly more common in men than women. No one knows what causes the disease, but 5% to 10% of all ALS cases occur within families. People with familial ALS live an average of only one to two years after symptoms appear.<\/p><\/blockquote>\n

ALS is quickly becoming a veteran issue since the disease is twice as likely to appear in veterans than in the general population, although neurologists can’t explain why. From the ALS Association<\/a>;<\/p>\n

Scientists have yet to find a cause for why America\u2019s military veterans are approximately twice as likely to develop ALS than other segments of our population. The U.S. Department of Veterans Affairs recognizes ALS as a service-connected disease and provides financial and medical support to those with at least 90 continuous days of military service.<\/p>\n

Study after study continues to demonstrate this to be true: If you serve in the military, regardless of the branch of service, regardless of whether you served in the Persian Gulf War, Vietnam, Korea, or World War II, and regardless of whether you served during a time of peace or a time of war, you are at a greater risk of dying from ALS than if you had not served in the military.<\/p>\n

Factors that might contribute to the increased risk of ALS in veterans include exposure to lead, pesticides or other environmental contacts. <\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"

CNN reports that the Federal Drug Administration has approved a new drug to treat amyotrophic lateral … FDA approves new ALS drug<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[],"class_list":["post-71906","post","type-post","status-publish","format-standard","hentry","category-veteran-health-care"],"_links":{"self":[{"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=\/wp\/v2\/posts\/71906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71906"}],"version-history":[{"count":0,"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=\/wp\/v2\/posts\/71906\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.azuse.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}